(Q40565158)

21 September 2017

Treatment of relapsed or refractory acute myeloid leukemia with humanized anti-CD33 monoclonal antibody HuM195. (English)

1 reference

21 September 2017

acute myeloid leukemia

1 reference

Feldman E

1

1 reference

21 September 2017

Kalaycio M

2

1 reference

21 September 2017

Weiner G

3

1 reference

21 September 2017

Frankel S

4

1 reference

21 September 2017

Schulman P

5

1 reference

21 September 2017

Schwartzberg L

6

1 reference

21 September 2017

Jurcic J

7

1 reference

21 September 2017

Velez-Garcia E

8

1 reference

21 September 2017

Seiter K

9

1 reference

21 September 2017

Scheinberg D

10

1 reference

21 September 2017

Levitt D

11

1 reference

21 September 2017

Wedel N

12

1 reference

21 September 2017

1 February 2003

1 reference

21 September 2017

1 reference

21 September 2017

17

1 reference

21 September 2017

2

1 reference

21 September 2017

314-318

1 reference

https://scigraph.springernature.com/pub.10.1038/sj.leu.2402803

21 September 2017

0 references

cites work

Design and analysis of trials of salvage therapy in acute myelogenous leukemia

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2402803

Efficacy of intensive chemotherapy for acute myelogenous leukemia associated with a preleukemic syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2402803

A phase I trial of monoclonal antibody M195 in acute myelogenous leukemia: specific bone marrow targeting and internalization of radionuclide

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2402803

The relationship between bcl-2 expression and response to chemotherapy in acute leukaemia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2402803

Tolerability in patients receiving trastuzumab with or without chemotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2402803

Surface expression and function of p75/AIRM-1 or CD33 in acute myeloid leukemias: engagement of CD33 induces apoptosis of leukemic cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2402803

p75/AIRM1 and CD33, two sialoadhesin receptors that regulate the proliferation or the survival of normal and leukemic myeloid cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2402803

Efficacy and safety of gemtuzumab ozogamicin in patients with CD33-positive acute myeloid leukemia in first relapse

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2402803

Characterization of murine and humanized anti-CD33, gelonin immunotoxins reactive against myeloid leukemias

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2402803

inferred from DOI database lookup

7 January 2021

based on heuristic

Dose-escalation trial of M195 labeled with iodine 131 for cytoreduction and marrow ablation in relapsed or refractory myeloid leukemias

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2402803

inferred from DOI database lookup

7 January 2021

based on heuristic

Identifiers

DOI

10.1038/SJ.LEU.2402803

1 reference

Dimensions Publication ID

21 September 2017

0 references

1 reference